New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- Karolinska Institutet Science Park
- Banvaktsvägen 22
- Solna , SE-171 48
Kancera AB is a biotechnology company that focuses on the development and sale of drug candidates that have the potential to cure or to stop the progression of cancer. Kancera is currently running two pharmaceutical development projects, one relating to solid tumors and one relating to leukemia. Through a subsidiary, Kancera also provides big pharma, mid-sized pharma and biotech companies with lead identification and optimization services such as high-throughput screening (HTS), fragment-based screening (FBS), assay development and medicinal chemistry.